Assenagon Asset Management
ALXN

Assenagon Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Assenagon Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,426,193
Closed -$262M – 1491
2021
Q2 		$262M Buy
+1,426,193
New +$245M 0.89% 19
2021
Q1 		– Sell
-363,434
Closed -$56.8M – 1361
2020
Q4 		$56.8M Sell
363,434
-351,606
-49% -$45.2M 0.25% 81
2020
Q3 		$81.8M Buy
715,040
+337,045
+89% +$36.4M 0.46% 36
2020
Q2 		$42.4M Buy
+377,995
New +$40.1M 0.27% 66
2020
Q1 		– Sell
-102,779
Closed -$11.1M – 1058
2019
Q4 		$11.1M Sell
102,779
-20,477
-17% -$2.19M 0.07% 175
2019
Q3 		$12.1M Buy
123,256
+106,189
+622% +$12M 0.08% 154
2019
Q2 		$2.23M Buy
+17,067
New +$2.2M 0.02% 490
2019
Q1 		– Sell
-104,434
Closed -$10.2M – 1179
2018
Q4 		$10.2M Sell
104,434
-17,721
-15% -$2.09M 0.12% 147
2018
Q3 		$17M Sell
122,155
-191,289
-61% -$24M 0.17% 123
2018
Q2 		$38.9M Buy
313,444
+241,846
+338% +$28.3M 0.45% 60
2018
Q1 		$7.98M Sell
71,598
-431,277
-86% -$51.5M 0.1% 180
2017
Q4 		$60.1M Sell
502,875
-381,275
-43% -$46.4M 0.62% 30
2017
Q3 		$124M Buy
884,150
+864,967
+4,509% +$118M 1.15% 18
2017
Q2 		$2.33M Buy
+19,183
New +$2.23M 0.05% 116

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Assenagon Asset Management's ALXN Position: Q3 2021 in Review

Assenagon Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,426,193 shares — an estimated $262M sold.

Assenagon Asset Management first reported a position in ALXN in Q2 2017 and held it in 14 quarters. The position peaked at $262M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Assenagon Asset Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Assenagon Asset Management sold 1,426,193 Alexion Pharmaceuticals shares in Q3 2021, an estimated $262M.
  • Assenagon Asset Management first reported a position in Alexion Pharmaceuticals in Q2 2017 and held it in 14 quarters.
  • Assenagon Asset Management's Alexion Pharmaceuticals position peaked at $262M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Assenagon Asset Management's 13F filing for Q3 2021, filed 19 Oct 2021.